Chemoresistance and targeted therapies in ovarian and endometrial cancers
about
Identification of novel diagnostic and prognostic miRNA signatures in endometrial cancer.Therapeutic utility of natural estrogen receptor beta agonists on ovarian cancer.The molecular mechanisms of chemoresistance in cancers.Evaluation of the combination of the dual m-TORC1/2 inhibitor vistusertib (AZD2014) and paclitaxel in ovarian cancer models.Exosomes in Nasopharyngeal Carcinoma.ADAM17 inhibition enhances platinum efficiency in ovarian cancer.Potential signaling pathways as therapeutic targets for overcoming chemoresistance in mucinous ovarian cancer.Ruxolitinib synergistically enhances the anti-tumor activity of paclitaxel in human ovarian cancer.Cisplatin-induced ERK1/2 activity promotes G1 to S phase progression which leads to chemoresistance of ovarian cancer cells.Inhibition of CRM1 activity sensitizes endometrial and ovarian cell lines to TRAIL-induced cell death.Modeling Endometrial Cancer: Past, Present, and FutureImaging and therapy of ovarian cancer: clinical application of nanoparticles and future perspectives
P2860
Q41024459-9F29FE10-F3E6-483F-97F8-36C0224B5E74Q41472874-677B6120-44AD-4A49-AA05-48E644416836Q41709101-7F9054DC-A53D-4695-A222-3543460A8E14Q49393542-5799D9A8-0D3E-46A8-92A9-C90F4AC033C1Q52340925-1A3541F4-1220-44C5-9716-27B3CD4AB258Q52584359-83B7DF66-7209-409C-ABF6-80CDD87FAD8FQ52643559-3FFDD736-97B2-48A3-A908-D1C744C95B52Q55084775-DEAFEE24-01CF-47F9-B542-BA1DF9A760B6Q55122746-75AC6AEF-4A77-4462-BE46-1FE231EA27D1Q55553003-09DDCF37-CAA3-49D0-8FCC-CAB6C117ADC6Q57170070-2069CDFB-C7F1-4C92-B36D-B317050B629BQ57174233-4A7704D2-2514-4606-9840-219CDF5D183C
P2860
Chemoresistance and targeted therapies in ovarian and endometrial cancers
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
2016年论文
@zh
2016年论文
@zh-cn
name
Chemoresistance and targeted therapies in ovarian and endometrial cancers
@ast
Chemoresistance and targeted therapies in ovarian and endometrial cancers
@en
Chemoresistance and targeted therapies in ovarian and endometrial cancers
@nl
type
label
Chemoresistance and targeted therapies in ovarian and endometrial cancers
@ast
Chemoresistance and targeted therapies in ovarian and endometrial cancers
@en
Chemoresistance and targeted therapies in ovarian and endometrial cancers
@nl
prefLabel
Chemoresistance and targeted therapies in ovarian and endometrial cancers
@ast
Chemoresistance and targeted therapies in ovarian and endometrial cancers
@en
Chemoresistance and targeted therapies in ovarian and endometrial cancers
@nl
P2093
P2860
P921
P356
P1433
P1476
Chemoresistance and targeted therapies in ovarian and endometrial cancers
@en
P2093
Eric Asselin
Kevin Brasseur
Nicolas Gévry
P2860
P356
10.18632/ONCOTARGET.14021
P407
P5008
P577
2016-12-19T00:00:00Z
2017-01-17T00:00:00Z